We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+39.82%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11.4B
AUM Growth
+$3.47B
Cap. Flow
+$1.27B
Cap. Flow %
11.12%
Top 10 Hldgs %
37.58%
Holding
169
New
25
Increased
27
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$384M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$292M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$154M
4
PFE icon
Pfizer
PFE
+$133M
5
UNH icon
UnitedHealth
UNH
+$131M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$259M
2
XLRN
Acceleron Pharma
XLRN
+$67.6M
3
ASND icon
Ascendis Pharma A/S
ASND
+$65.8M
4
EXEL icon
Exelixis
EXEL
+$58.8M
5
BIIB icon
Biogen
BIIB
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98.2%
2 Financials 0.52%
3 Technology 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRLD icon
1
Prelude Therapeutics
PRLD
$370M
$1.12B 9.76%
15,594,877
– –
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$537M 4.7%
7,406,307
– –
PMVP icon
3
PMV Pharmaceuticals
PMVP
$58.7M
$451M 3.95%
7,330,423
– –
SPRY icon
4
ARS Pharmaceuticals
SPRY
$563M
$405M 3.54%
+8,740,887
New +$292M
ABCL icon
5
AbCellera Biologics
ABCL
$1.62B
$338M 2.96%
+8,400,768
New +$384M
TPTX
6
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$335M 2.93%
2,745,327
– –
PRVL
7
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$319M 2.79%
13,822,463
– –
IOVA icon
8
Iovance Biotherapeutics
IOVA
$2.1B
$308M 2.7%
6,645,100
– –
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$252M 2.2%
1,145,300
-171,700
-13% -$37.1M
BSX icon
10
Boston Scientific
BSX
$68.5B
$235M 2.05%
6,523,000
+1,675,700
+35% +$60.4M
BMY icon
11
Bristol-Myers Squibb
BMY
$130B
$220M 1.93%
3,549,100
– –
HZNP
12
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$220M 1.93%
3,008,755
– –
MRK icon
13
Merck
MRK
$326B
$218M 1.9%
2,786,946
+73,569
+3% +$5.63M
NTRA icon
14
Natera
NTRA
$36.1B
$210M 1.84%
2,110,700
– –
VRTX icon
15
Vertex Pharmaceuticals
VRTX
$124B
$197M 1.73%
834,100
+168,000
+25% +$38.5M
PASG icon
16
Passage Bio
PASG
$14.7M
$178M 1.56%
348,145
– –
ARQT icon
17
Arcutis Biotherapeutics
ARQT
$3.55B
$171M 1.5%
6,073,850
+1,400,000
+30% +$34.3M
AFIB
18
DELISTED
Acutus Medical Inc
AFIB
$158M 1.38%
5,477,958
– –
KNTE
19
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$153M 1.34%
+3,847,929
New +$154M
UNH icon
20
UnitedHealth
UNH
$389B
$137M 1.2%
+390,300
New +$131M
PFE icon
21
Pfizer
PFE
$144B
$133M 1.16%
+3,616,600
New +$133M
CALC icon
22
CalciMedica
CALC
$11.3M
$130M 1.14%
319,703
– –
BIIB icon
23
Biogen
BIIB
$30.4B
$130M 1.13%
529,400
-186,500
-26% -$48.1M
NBIX icon
24
Neurocrine Biosciences
NBIX
$18.4B
$125M 1.09%
1,301,715
– –
CNC icon
25
Centene
CNC
$31.6B
$120M 1.05%
1,993,700
+658,000
+49% +$41.8M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2020 Portfolio in Review

As of Q4 2020, OrbiMed held 169 positions worth $11.4B, up 44% from $7.96B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $1.27B of net new capital in Q4 2020, opening 25 new positions and adding to 27 existing holdings. Its largest new stake was AbCellera Biologics: 8,400,768 shares worth $338M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $259M trimmed.

  • OrbiMed's largest Q4 2020 buy was AbCellera Biologics: 8,400,768 shares worth $338M.
  • OrbiMed added most to Xtant Medical Holdings in Q4 2020, an estimated $81.8M increase.
  • OrbiMed's biggest Q4 2020 reduction was Alexion Pharmaceuticals, cutting an estimated $259M.
  • OrbiMed fully exited Acceleron Pharma in Q4 2020, selling an estimated $67.6M.
  • OrbiMed's ten largest holdings make up 38% of its $11.4B portfolio in Q4 2020.
  • OrbiMed opened 25 new positions and closed 20 in Q4 2020.
  • OrbiMed's portfolio value rose 44% quarter-over-quarter to $11.4B.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.